Search Results

There are 7908 results for: content related to: Vemurafenib-Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma

  1. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Version of Record online : 8 APR 2014, DOI: 10.1111/ajco.12200

  2. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Version of Record online : 2 FEB 2015, DOI: 10.1002/prp2.113

  3. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation

    The Journal of Dermatology

    Volume 42, Issue 9, September 2015, Pages: 881–888, Mi Ryung Roh, Jung Min Kim, Sang Hee Lee, Hong Sun Jang, Kyu Hyun Park, Kee Yang Chung and Sun Young Rha

    Version of Record online : 5 JUN 2015, DOI: 10.1111/1346-8138.12950

  4. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 967–981, Navnit Shah, Raman M. Iyer, Hans-Juergen Mair, Duk Soon Choi, Hung Tian, Ralph Diodone, Karsten Fähnrich, Anni Pabst-Ravot, Kin Tang, Emmanuel Scheubel, Joseph F. Grippo, Sebastian A. Moreira, Zenaida Go, James Mouskountakis, Theresa Louie, Prabha N. Ibrahim, Harpreet Sandhu, Linda Rubia, Hitesh Chokshi, Dharmendra Singhal and Waseem Malick

    Version of Record online : 29 DEC 2012, DOI: 10.1002/jps.23425

  5. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 987–994, R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin and L. Fearfield

    Version of Record online : 29 OCT 2012, DOI: 10.1111/bjd.12010

  6. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  7. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

    British Journal of Dermatology

    Volume 173, Issue 4, October 2015, Pages: 1024–1031, R. Sinha, J. Larkin, M. Gore and L. Fearfield

    Version of Record online : 11 OCT 2015, DOI: 10.1111/bjd.13958

  8. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib

    Pediatric Dermatology

    Volume 34, Issue 3, May/June 2017, Pages: 337–341, Nika Finelt, Rishi R. Lulla, Hector Melin-Aldana, Jennifer Shuley Ruth, Frank Y. Lin, Jack M. Su, Crystal Y. Pourciau, Raegan D. Hunt and Brandi M. Kenner-Bell

    Version of Record online : 19 MAY 2017, DOI: 10.1111/pde.13148

  9. Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 9, September 2015, Pages: 1797–1806, R. Mössner, L. Zimmer, C. Berking, C. Hoeller, C. Loquai, E. Richtig, K.C. Kähler, J.C. Hassel, R. Gutzmer and S. Ugurel

    Version of Record online : 6 MAR 2015, DOI: 10.1111/jdv.13039

  10. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

    The Journal of Clinical Pharmacology

    Volume 54, Issue 4, April 2014, Pages: 368–374, Antoni Ribas, Weijiang Zhang, Ilsung Chang, Keisuke Shirai, Marc S. Ernstoff, Adil Daud, C. Lance Cowey, Gregory Daniels, Elizabeth Seja, Elizabeth O'Laco, John A. Glaspy, Bartosz Chmielowski, Todd Hill, Andrew K. Joe and Joseph F. Grippo

    Version of Record online : 22 JAN 2014, DOI: 10.1002/jcph.255

  11. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

    British Journal of Dermatology

    Volume 171, Issue 6, December 2014, Pages: 1529–1532, C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau, S. Allouche and L. Verneuil

    Version of Record online : 9 NOV 2014, DOI: 10.1111/bjd.13300

  12. You have full text access to this OnlineOpen article
    Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

    Cancer Medicine

    Volume 4, Issue 8, August 2015, Pages: 1205–1213, Geoffrey T. Gibney, Geneviève Gauthier, Charles Ayas, Philip Galebach, Eric Q. Wu, Sarang Abhyankar, Carolina Reyes, Annie Guérin and Yeun Mi Yim

    Version of Record online : 20 MAY 2015, DOI: 10.1002/cam4.475

  13. You have full text access to this OnlineOpen article
    Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state

    Molecular Systems Biology

    Volume 13, Issue 1, January 2017, Mohammad Fallahi-Sichani, Verena Becker, Benjamin Izar, Gregory J Baker, Jia-Ren Lin, Sarah A Boswell, Parin Shah, Asaf Rotem, Levi A Garraway and Peter K Sorger

    Version of Record online : 9 JAN 2017, DOI: 10.15252/msb.20166796

  14. You have free access to this content
    Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

    Cancer

    Volume 120, Issue 14, 15 July 2014, Pages: 2158–2163, Vincent Launay-Vacher, Sarah Zimner-Rapuch, Nicolas Poulalhon, Thibault Fraisse, Valérie Garrigue, Morgane Gosselin, Sabine Amet, Nicolas Janus and Gilbert Deray

    Version of Record online : 15 APR 2014, DOI: 10.1002/cncr.28709

  15. PTEN regulates IGF-1R-mediated therapy resistance in melanoma

    Pigment Cell & Melanoma Research

    Volume 28, Issue 5, September 2015, Pages: 572–589, Jun Wang, Tobias Sinnberg, Heike Niessner, Rebecca Dölker, Birgit Sauer, Wolfgang E. Kempf, Friedegund Meier, Nick Leslie and Birgit Schittek

    Version of Record online : 16 AUG 2015, DOI: 10.1111/pcmr.12390

  16. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma

    Journal of Cutaneous Pathology

    Volume 41, Issue 3, March 2014, Pages: 326–328, Penvadee Pattanaprichakul, Michael T. Tetzlaff, Whitney J. Lapolla, Carlos A. Torres-Cabala, Madeleine Duvic, Victor G. Prieto, Kenneth Y. Tsai and Jonathan L. Curry

    Version of Record online : 24 DEC 2013, DOI: 10.1111/cup.12273

  17. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

    Journal of Cutaneous Pathology

    Volume 41, Issue 6, June 2014, Pages: 539–543, Inbal Braunstein, Tara C. Gangadhar, Rosalie Elenitsas and Emily Y. Chu

    Version of Record online : 11 MAR 2014, DOI: 10.1111/cup.12318

  18. You have full text access to this OnlineOpen article
    Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

    EMBO Molecular Medicine

    Volume 7, Issue 9, September 2015, Pages: 1104–1118, Kristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, Aida Shahrabi, Fleur Weeber, Ji-Ying Song, Thomas Kuilman, Daniel J Vis, Lodewyk F Wessels, Emile E Voest, Ton NM Schumacher, Christian U Blank, David J Adams, John B Haanen and Daniel S Peeper

    Version of Record online : 23 JUN 2015, DOI: 10.15252/emmm.201404914

  19. Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

    Pigment Cell & Melanoma Research

    Volume 28, Issue 3, May 2015, Pages: 318–323, Marlous Hoogstraat, Christa G. Gadellaa-van Hooijdonk, Inge Ubink, Nicolle J. M. Besselink, Mark Pieterse, Wouter Veldhuis, Marijn van Stralen, Eelco F. J. Meijer, Stefan M. Willems, Michael A. Hadders, Thomas Kuilman, Oscar Krijgsman, Daniel S. Peeper, Marco J. Koudijs, Edwin Cuppen, Emile E. Voest and Martijn P. Lolkema

    Version of Record online : 7 JAN 2015, DOI: 10.1111/pcmr.12347

  20. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

    Journal of Cutaneous Pathology

    Volume 40, Issue 7, July 2013, Pages: 667–669, Gene H. Kim, Alan Levy and Goli Compoginis

    Version of Record online : 15 APR 2013, DOI: 10.1111/cup.12149